Six-month Survival of Patients with Malignant Distal Biliary Stricture Following Endoscopic Biliary Stent Procedure and Its Associated Factors

Luki Kusumaningtyas, Dadang Makmun, Ari Fahrial Syam, Siti Setiati


Background: unresectable malignant distal biliary stricture patients require endoscopic biliary stent placement procedure. The survival rate and its associated factors in Indonesia are unknown. Objectives. To identify 6-month survival of patients with malignant distal biliary stricture following endoscopic biliary stent procedure and its associated factors. Methods: a retrospective cohort study was conducted using medical records of patients with unresectable malignant distal biliary stricture, which involved caput of pancreas, ampulla of Vater or distal cholangiocarcinoma following endoscopic biliary stent procedure between June 2015 and August 2017 at Cipto Mangunkusumo National Central General Hospital. The cumulative survival was defined by using the Kaplan-Meier curve. Bivariate and multivariate analyses were performed using Cox regression of some factors including failure of biliary stent insertion, bleeding, sepsis, comorbidities, malnutrition, and serum albumin levels. Results: out of total 120 subjects, 85 subjects died within 6 months following the stent procedure with a proportion of 180-day survival of 24% and a median survival of 81 days (CI 95%: 56–106 days). In bivariate analysis, factors of comorbidities, sepsis, malnutrition and albumin levels ≤ 3.0 g/dL had p values of < 0.25; while the subsequent multivariate analysis showed that albumin level of ≤ 3.0 g/dL had HR of 2.73 (CI 95%: 1.48 – 5.05; p = 0.001). Conclusion: the 6-month survival following endoscopic biliary stent procedure is 24% with a median survival of 81 days. Albumin level of ≤ 3.0 g/dL has a 2.73 times greater risk for 6-month mortality rate.


survival; malignant distal biliary stricture; endoscopic biliary stenting; mortality-related factors; albumin


Oto BT, Fauzi A, Syam AF, et al. Identification and stenting of malignant obstructive jaundice : determining the success rates of ERCP. Indones J Gastroenterol Hepatol Dig Endosc. 2012;13(1):19–22.

Kurniawan J, Hasan I, Gani RA, Simadibrata M. Mortality-related factors in patients with malignant obstructive jaundice. Acta Med Indones-Indones J Intern Med. 2016;48(4):282–8.

Yunihastuti E, Lesmana LA, Syam AF, Hasan I. Non-surgical biliary drainage on biliary obstruction due to malignancy. Indones J Gastroenterol, Hepatol, Dig Endosc. 2001;2(2):8–20.

Luo J, Xiao L, Wu C, Zheng Y, Zhao N. The incidence and survival rate of population-based pancreatic cancer patients: Shanghai cancer registry 2004–2009. PLoS ONE. 2013;8(10):1-7, e76052.

Makmun D, Fauzi A, Abdullah M, Syam AF. The role of EUS-BD in the management of malignant biliary obstruction: The Indonesian perspective. Diagn Ther Endosc. 2017;1–8.

Pu LZCT, Singh R, Loong CK, de Moura EGH. Malignant biliary obstruction: evidence for best practice. Gastroenterol Res Pract. 2016;1–7.

Prat F, Chapat O, Ducot B, et al. Predictive factors for survival of patients with inoperable malignant distal biliary strictures: a practical management guideline. 1998;76–80.

Moghimi M, Marashi SA, Salehian MT, Sheikhvatan M. Obstructive jaundice in Iran: factors affecting early outcome. 2008;7(5):515–9.

Afshar M, Khanom K, Ma YT, Punia P. Biliary stenting in advanced malignancy: an analysis of predictive factors for survival. Cancer Manag Res. 2014;6:475–9.

Tipsunthonsak N, Piriyasupong T, Piriyaskanon A. Efficacy of iliary stent drainage and factors associated with complications in endoscopic palliative treatment of patients with hilar cholangiocarcinoma. THAI J Surg. 2011;32:26–34.

Waghray A, Sobotka A, Marrero CR, Estfan B, Aucejo F, Menon KVN. Serum albumin predicts survival in patients with hilar cholangiocarcinoma. 2017;5:62–6.

Sitompul R, Fauzi A, Makmun D, Abdulah M, Fahrial A, Marcellus S. Post-endoscopic retrograde cholangio-pancreatography complications at Dr . Cipto Mangunkusumo General National Hospital. Indones J Gastroenterol Hepatol Dig Endosc. 2009;10(2):41–5.

Liao W, Angsuwatcharakon P, Isayama H, Dhir V. International consensus recommendations for difficult biliary access. Gastrointest Endosc. 2017;85(2):295–304.

Chalya PL, Kanumba ES, Mchembe M. Etiological spectrum and treatment outcome of obstructive jaundice at a university teaching hospital in northwestern Tanzania: A diagnostic and therapeutic challenges. BMC Res Notes. 2011;4(1):147.

Saudale A, Gani R, Rumende C. Kesintasan satu tahun kanker pankreas dan faktor-faktor yang memengaruhinya. Universitas Indonesia; 2018.

Paik WH, Lee TH, Park DH, et al. EUS-guided biliary drainage versus ERCP for the primary palliation of malignant biliary obstruction: A multicenter randomized clinical trial. Am J Gastroenterol. 2018;113(7):987–97.

Nakai Y, Isayama H, Sasaki T, et al. Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy. Crit Rev Oncol Hematol. 2011;78(3):252–9.

Chang C, Yin W, Wei C, Wu C, Su Y. Adjusted age-adjusted Charlson Comorbidity Index score as a risk measure of perioperative mortality before cancer surgery. PLoS One. 2016;09:1–16.

Afaneh C, Gerszberg D, Slattery E, Seres DS, Chabot JA, Kluger MD. Pancreatic cancer surgery and nutrition management: a review of the current literature. Hepato Biliary Surg Nutr. 2015;4(1):59-71.

Park J, Kim M, Kim K, et al. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy : A large-scale observational study. Gut Liver. 2009;3(4):298–305.

Akirov A, Masri-Iraqi H, Atamna A, Shimon I. Low albumin levels are associated with mortality risk in hospitalized patients. Am J Med. 2017;130(12):1465.e11-1465.e19.

Full Text: PDF


  • There are currently no refbacks.